Lakefront Biotherapeutics (LKFT) Convertible Debt (2025 - 2026)

Lakefront Biotherapeutics (LKFT) reported Convertible Debt of $25.3 million for Q1 2026, up 2.48% quarter-over-quarter from $24.6 million in Q4 2025.

Lakefront Biotherapeutics (LKFT) Convertible Debt (2025 - 2026) Analysis & Trends

Lakefront Biotherapeutics (LKFT) has 2 years of Convertible Debt data on file, last reported at $25.3 million in Q1 2026.

Convertible Debt for Q1 2026 came in at $25.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $25.3 million (changed N/A YoY), and the FY2025 annual result was $24.6 million, changed N/A from the prior year.
Convertible Debt climbed to $25.3 million in Q1 2026 per LKFT's latest filing, from $24.6 million in the prior quarter.
Over five years, Convertible Debt peaked at $25.3 million in Q1 2026 and troughed at $23.0 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Lakefront Biotherapeutics	9.64 Bn	9.64 Bn	1.97 Mn

Download Data